Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced EGFR-mutant NSCLC with Primary Resistance to EGFR-TKIs：a retrospective cohort Study.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-07-07 DOI:10.1159/000546834

Yonghong Li, Yirui Liu, Yi Peng, Jing Tang, Xiaobing Li

{"title":"Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced EGFR-mutant NSCLC with Primary Resistance to EGFR-TKIs：a retrospective cohort Study.","authors":"Yonghong Li, Yirui Liu, Yi Peng, Jing Tang, Xiaobing Li","doi":"10.1159/000546834","DOIUrl":null,"url":null,"abstract":"Objective: To explore effective treatment strategies for EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors) primary resistant advanced non-small cell lung cancer (NSCLC).Methods: We collected data on the efficacy and safety of chemotherapy combined with anlotinib in patients with EGFR-TKI primary resistant advanced NSCLC. The primary endpoints of this study were overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and treatment-related adverse events (AEs).Results: A total of 34 patients were enrolled. The preliminary results demonstrate that ORR and DCR of chemotherapy combined with anlotinib in patients with EGFR-TKI primary resistant advanced NSCLC were 32.35% and 64.71%, respectively. The median PFS and OS were 5 months and 9 months, respectively. In addition to efficacy, common adverse effects included myelosuppression, hypertension, proteinuria, and hand-foot syndrome. These were generally mild and well-tolerated, indicating that this regimen has promising prospects for overcoming EGFR-TKI primary resistance in advanced NSCLC.Conclusion: The combination of chemotherapy and anlotinib shows promising efficacy in patients with primary EGFR TKI-resistant advanced NSCLC, with a manageable safety profile. This regimen offers a potential new treatment option for this challenging patient population. Further studies are warranted to confirm these findings and explore long-term outcomes.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546834","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore effective treatment strategies for EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors) primary resistant advanced non-small cell lung cancer (NSCLC).

Methods: We collected data on the efficacy and safety of chemotherapy combined with anlotinib in patients with EGFR-TKI primary resistant advanced NSCLC. The primary endpoints of this study were overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and treatment-related adverse events (AEs).

Results: A total of 34 patients were enrolled. The preliminary results demonstrate that ORR and DCR of chemotherapy combined with anlotinib in patients with EGFR-TKI primary resistant advanced NSCLC were 32.35% and 64.71%, respectively. The median PFS and OS were 5 months and 9 months, respectively. In addition to efficacy, common adverse effects included myelosuppression, hypertension, proteinuria, and hand-foot syndrome. These were generally mild and well-tolerated, indicating that this regimen has promising prospects for overcoming EGFR-TKI primary resistance in advanced NSCLC.

Conclusion: The combination of chemotherapy and anlotinib shows promising efficacy in patients with primary EGFR TKI-resistant advanced NSCLC, with a manageable safety profile. This regimen offers a potential new treatment option for this challenging patient population. Further studies are warranted to confirm these findings and explore long-term outcomes.

查看原文本刊更多论文

化疗联合安洛替尼治疗原发性EGFR-TKIs耐药的晚期egfr突变NSCLC的疗效和安全性：一项回顾性队列研究

目的：探讨表皮生长因子受体酪氨酸激酶抑制剂EGFR-TKI原发性耐药晚期非小细胞肺癌（NSCLC）的有效治疗策略。方法：收集化疗联合安洛替尼治疗EGFR-TKI原发性耐药晚期NSCLC患者的疗效和安全性数据。该研究的主要终点是总缓解率（ORR）、无进展生存期（PFS）、疾病控制率（DCR）、总生存期（OS）和治疗相关不良事件（ae）。结果：共纳入34例患者。初步结果显示，化疗联合安洛替尼治疗EGFR-TKI原发性耐药晚期NSCLC患者的ORR和DCR分别为32.35%和64.71%。中位PFS和OS分别为5个月和9个月。除疗效外，常见的不良反应包括骨髓抑制、高血压、蛋白尿和手足综合征。这些通常是温和且耐受性良好的，表明该方案在克服晚期NSCLC中EGFR-TKI的原发性耐药方面具有良好的前景。结论：化疗联合安洛替尼治疗原发性EGFR tki耐药晚期NSCLC疗效良好，安全性可控。该方案为这一具有挑战性的患者群体提供了一种潜在的新治疗选择。需要进一步的研究来证实这些发现并探索长期结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.